Beam Therapeutics is a biotechnology company committed to creating a new class of precision genetic medicines based on our proprietary base editing technology, with a vision of providing life-long cures to patients suffering from serious diseases.
Recent Press Releases
May 26, 2020
May 12, 2020
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results
April 28, 2020
Beam Therapeutics to Present Updated Data Highlighting Base Editing Programs for Sickle Cell Disease at 23rd ASGCT Annual Meeting